This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hohaus, S. Articles by Leone, G. Search for Related Content PubMed PubMed Citation Articles by Hohaus, S. Articles by Leone, G.

Association between Glutathione S-Transferase Genotypes and Hodgkin’s Lymphoma Risk and Prognosis¹

Istituto di Ematologia, Universita’ Cattolica S. Cuore, 00168 Rome, Italy

Purpose: The interplay between genetic susceptibility and exposure to carcinogens has been shown to be involved in the etiology of many solid tumors. We studied the frequency and clinical correlates of polymorphisms resulting in deletions of two genes involved in the detoxification of potentially carcinogenic agents, glutathione S-transferase (GST)-M1 and GSTT1 in patients with Hodgkin’s lymphoma (HL).

Experimental Design: The prevalence of gene deletions in 90 patients with HL was compared with a case-matched cohort of 176 normal blood donors. GST gene polymorphisms were studied using a multiplex PCR method, including the BCL2 gene as an internal control.

Results: Deletions of the GSTT1 gene were more frequent in cases compared with controls (28.9 versus 17.6%, P = 0.04), resulting in an increased risk for HL in individuals with the GSTT1-null genotype (odds risk, 1.9; 95% confidence interval 1.04–3.46). The GSTT1-null genotype particularly increased the HL risk in females aged <45 years (odds risk 6.1, 95% confidence interval 1.6–23, P = 0.008). Correlating patient characteristics to genotype, we found an association between the GSTT1-null genotype and a limited stage of disease (I/IIA versus IIB-IV, 40.6 versus 19.6%, P = 0.047) and an erythrocyte sedimentation rate of <50 mm/h (P = 0.02). Patients with at least one GST deletion (GSTM1- or GSTT1-) had a significant better disease-free survival when compared with those with undeleted GST genes (GSTM1+/GSTT1+; P = 0.012).

Conclusions: The GSTT1-null genotype may increase the risk for HL and is associated with favorable prognostic factors, and the presence of at least one GST deletion indicates an improved disease-free survival.

This article has been cited by other articles:

				V. Ribrag, S. Koscielny, O. Casasnovas, C. Cazeneuve, P. Brice, F. Morschhauser, J. Gabarre, A. Stamatoullas, G. Lenoir, G. Salles, et al. Pharmacogenetic study in Hodgkin lymphomas reveals the impact of UGT1A1 polymorphisms on patient prognosis Blood, April 2, 2009; 113(14): 3307 - 3313. [Abstract] [Full Text] [PDF]

				L. A. Anderson, R. M. Pfeiffer, J. S. Rapkin, G. Gridley, L. Mellemkjaer, K. Hemminki, M. Bjorkholm, N. E. Caporaso, and O. Landgren Survival Patterns Among Lymphoma Patients With a Family History of Lymphoma J. Clin. Oncol., October 20, 2008; 26(30): 4958 - 4965. [Abstract] [Full Text] [PDF]

				S. Y. Kristinsson, M. Bjorkholm, L. R. Goldin, M. L. McMaster, I. Turesson, and O. Landgren Risk of lymphoproliferative disorders among first-degree relatives of lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia patients: a population-based study in Sweden Blood, October 15, 2008; 112(8): 3052 - 3056. [Abstract] [Full Text] [PDF]

				X. Guo, S. J. O'Brien, Y. Zeng, G. W. Nelson, and C. A. Winkler GSTM1 and GSTT1 Gene Deletions and the Risk for Nasopharyngeal Carcinoma in Han Chinese Cancer Epidemiol. Biomarkers Prev., July 1, 2008; 17(7): 1760 - 1763. [Abstract] [Full Text] [PDF]

				S Hohaus, M Giachelia, A Di Febo, M Martini, G Massini, B Vannata, F D'Alo', F Guidi, M Greco, F Pierconti, et al. Polymorphism in cytokine genes as prognostic markers in Hodgkin's lymphoma Ann. Onc., August 1, 2007; 18(8): 1376 - 1381. [Abstract] [Full Text] [PDF]

				C. F. Skibola, J. D. Curry, and A. Nieters Genetic susceptibility to lymphoma Haematologica, July 1, 2007; 92(7): 960 - 969. [Abstract] [Full Text] [PDF]

				P. Yang, J. O. Ebbert, Z. Sun, and R. M. Weinshilboum Role of the Glutathione Metabolic Pathway in Lung Cancer Treatment and Prognosis: A Review J. Clin. Oncol., April 10, 2006; 24(11): 1761 - 1769. [Abstract] [Full Text] [PDF]

				J.-M. Lee, M.-T. Wu, Y.-C. Lee, S.-Y. Yang, J.-S. Chen, H.-H. Hsu, P.-M. Huang, S.-W. Kuo, C.-J. Lee, and C.-J. Chen Association of GSTP1 Polymorphism and Survival for Esophageal Cancer Clin. Cancer Res., July 1, 2005; 11(13): 4749 - 4753. [Abstract] [Full Text] [PDF]

				S. Hohaus, A. Di Ruscio, A. Di Febo, G. Massini, F. D'Alo', F. Guidi, G. Mansueto, M. T. Voso, and G. Leone Glutathione S-transferase P1 Genotype and Prognosis in Hodgkin's Lymphoma Clin. Cancer Res., March 15, 2005; 11(6): 2175 - 2179. [Abstract] [Full Text] [PDF]